Merck Singulair Patent Survives USPTO Re-Exam
The U.S. Patent and Trademark Office has backed Merck & Co. Inc. in a re-examination of a patent covering the drugmaker's blockbuster asthma and allergy drug Singulair, finding that the disputed...To view the full article, register now.
Already a subscriber? Click here to view full article